Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2009, Article ID 543746, 11 pages
http://dx.doi.org/10.1155/2009/543746
Research Article

Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease

1Service d'Epidémiologie et de Santé Publique, Institut Pasteur de Lille, Lille; INSERM, U744, Lille; Université Nord de France, Lille; UDSL, 59019 Lille, France
2Kaiser Permanente Division of Research, Oakland, CA 94612, USA
3INSERM, U558, Toulouse, Department of Epidemiology, Paul Sabatier-Toulouse Purpan University, 31073 Toulouse, France
4The Department of Epidemiology and Public Health, Queen’s University Belfast, Belfast BT71NN, Northern Ireland, UK
5Department of Epidemiology and Public Health, EA 3430, University of Strasbourg, Faculty of Medicine, 67085 Strasbourg, France
6Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA 94305-5705, USA
7INSERM, U780, 94807 Villejuif, Hôpital Kremlin-Bicêtre, France
8Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA 94305, USA
9Stanford Human Genome Center, Stanford, CA 94304, USA
10Falk Cardiovascular Research Center, Stanford Falk Cardiovascular Research Building, Stanford, CA 94305-5406, USA

Received 11 June 2009; Accepted 26 August 2009

Academic Editor: Mostafa Badr

Copyright © 2009 Jean Dallongeville et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Lehrke and M. A. Lazar, “The many faces of PPARγ,” Cell, vol. 123, no. 6, pp. 993–999, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions,” Progress in Lipid Research, vol. 45, no. 2, pp. 120–159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Kostadinova, W. Wahli, and L. Michalik, “PPARs in diseases: control mechanisms of inflammation,” Current Medicinal Chemistry, vol. 12, no. 25, pp. 2995–3009, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. S. S. Deeb, L. Fajas, M. Nemoto et al., “A Pro12Ala substitution in PPARγ2associated with decreased receptor activity, lower body mass index and improved insulin sensitivity,” Nature Genetics, vol. 20, no. 3, pp. 284–287, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Meirhaeghe, L. Fajas, N. Helbecque et al., “A genetic polymorphism of the peroxisome proliferator-activated receptor γ gene influences plasma leptin levels in obese humans,” Human Molecular Genetics, vol. 7, no. 3, pp. 435–440, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Meirhaeghe, L. Fajas, F. Gouilleux et al., “A functional polymorphism in a STAT5B site of the human PPARγ3 gene promoter affects height and lipid metabolism in a French population,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 2, pp. 289–294, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Meirhaeghe, M. W. T. Tanck, L. Fajas et al., “Study of a new PPARγ2 promoter polymorphism and haplotype analysis in a French population,” Molecular Genetics and Metabolism, vol. 85, no. 2, pp. 140–148, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Meirhaeghe, D. Cottel, P. Amouyel, and J. Dallongeville, “Association between peroxisome proliferator-activated receptor γ haplotypes and the metabolic syndrome in French men and women,” Diabetes, vol. 54, no. 10, pp. 3043–3048, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. P. M. Ridker, N. R. Cook, S. Cheng et al., “Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 5, pp. 859–863, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Pischon, J. K. Pai, J. E. Manson et al., “Peroxisome proliferator-activated receptor-γ2P12A polymorphism and risk of coronary heart disease in US men and women,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 8, pp. 1654–1658, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. J. W. G. Yarnell, “The PRIME study: classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland,” QJM, vol. 91, no. 10, pp. 667–676, 1998. View at Google Scholar · View at Scopus
  12. P. Ducimetiere, J.-B Ruidavets, M. Montaye, B. Haas, and J. Yarnell, “Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50–59 in France and Northern Ireland: the prospective epidemiological study of myocardial infarction (PRIME) study,” International Journal of Epidemiology, vol. 30, no. 5, pp. 1057–1062, 2001. View at Google Scholar · View at Scopus
  13. G. H. Hughes, G. Cutter, R. Donahue et al., “Recruitment in the coronary artery disease risk development in young adults (cardia) study,” Controlled Clinical Trials, vol. 8, no. 4, supplement 1, pp. 68S–73S, 1987. View at Google Scholar · View at Scopus
  14. A. S. Go, C. Iribarren, M. Chandra et al., “Statin and β-blocker therapy and the initial presentation of coronary heart disease,” Annals of Internal Medicine, vol. 144, no. 4, pp. 229–238, 2006. View at Google Scholar · View at Scopus
  15. C. Iribarren, A. S. Go, G. Husson et al., “Metabolic syndrome and early-onset coronary artery disease. is the whole greater than its parts?” Journal of the American College of Cardiology, vol. 48, no. 9, pp. 1800–1807, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. Hlatky, E. Ashley, T. Quertermous et al., “Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease,” American Heart Journal, vol. 154, no. 6, pp. 1043–1051, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. T. L. Assimes, J. W. Knowles, A. Basu et al., “Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study,” Human Molecular Genetics, vol. 17, no. 15, pp. 2320–2328, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Slatkin and L. Excoffier, “Testing for linkage disequilibrium in genotypic data using the Expectation-Maximization algorithm,” Heredity, vol. 76, no. 4, pp. 377–383, 1996. View at Google Scholar · View at Scopus
  19. R. C. Lewontin, “The interaction of selection and linkage. I. General considerations; heterotic models,” Genetics, vol. 49, no. 1, pp. 49–67, 1964. View at Google Scholar
  20. D. A. Tregouet, S. Barbaux, S. Escolano et al., “Specific haplotypes of the P-selectin gene are associated with myocardial infarction,” Human Molecular Genetics, vol. 11, no. 17, pp. 2015–2023, 2002. View at Google Scholar · View at Scopus
  21. D. A. Tregouet, S. Escolano, L. Tiret, A. Mallet, and J. L. Golmard, “A new algorithm for haplotype-based association analysis: the stochastic-EM algorithm,” Annals of Human Genetics, vol. 68, no. 2, pp. 165–177, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. A. S. Doney, B. Fischer, G. Leese, A. D. Morris, and C. N. A. Palmer, “Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a go-DARTS study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 12, pp. 2403–2407, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Gallicchio, B. Kalesan, H. Y. Huang, P. Strickland, S. C. Hoffman, and K. J. Helzlsouer, “Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland,” PPAR Research, vol. 2008, Article ID 276581, 9 pages, 2008. View at Publisher · View at Google Scholar
  24. Review Manager (RevMan) [Computer program], Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
  25. C. C. Szeto, K.-M. Chow, P. Y.-K. Poon, B. C.-H. Kwan, and P. K.-T. Li, “Peroxisome proliferator-activated receptor-gamma gene polymorphism and risk of cardiovascular disease in patients with diabetic nephropathy,” American Journal of Nephrology, vol. 28, no. 5, pp. 715–722, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. E. A. Ruiz-Narváez, P. Kraft, and H. Campos, “Ala12 variant of the peroxisome proliferator-activated receptor-γ gene (PPARG) is associated with higher polyunsaturated fat in adipose tissue and attenuates the protective effect of polyunsaturated fat intake on the risk of myocardial infarction,” American Journal of Clinical Nutrition, vol. 86, no. 4, pp. 1238–1242, 2007. View at Google Scholar · View at Scopus
  27. L. Li, L.-X. Cheng, R. Nsenga, M.-A. He, and T.-C. Wu, “Association between Pro 12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population,” Clinical Cardiology, vol. 29, no. 7, pp. 300–304, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. M. D. Tobin, P. S. Braund, P. R. Burton et al., “Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study,” European Heart Journal, vol. 25, no. 6, pp. 459–467, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. U. Vogel, S. Segel, C. Dethlefsen et al., “PPARgamma Pro12Ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes,” BMC Medical Genetics, vol. 10, p. 52, 2009. View at Google Scholar
  30. L. Gallicchio, H. Chang, D. K. Christo et al., “Single nucleotide polymorphisms in inflammation-related genes and mortality in a community-based cohort in Washington County, Maryland,” American Journal of Epidemiology, vol. 167, no. 7, pp. 807–813, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. M. H. Zafarmand, Y. T. van der Schouw, D. E. Grobbee, P. W. de Leeuw, and M. L. Bots, “Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses,” Vascular Health and Risk Management, vol. 4, no. 2, pp. 427–436, 2008. View at Google Scholar
  32. E. J. Rhee, C. H. Kwon, W. Y. Lee et al., “No association of Pro12Ala polymorphism of PPAR-γ gene with coronary artery disease in Korean subjects,” Circulation Journal, vol. 71, no. 3, pp. 338–342, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Bluher, T. Klemm, T. Gerike, H. Krankenberg, G. Schuler, and R. Paschke, “Lack of association between peroxisome proliferator-activated receptor-γ-2 gene variants and the occurrence of coronary heart disease in patients with diabetes mellitus,” European Journal of Endocrinology, vol. 146, no. 4, pp. 545–551, 2002. View at Google Scholar · View at Scopus
  34. E. Iwata, I. Yamamoto, T. Motomura et al., “The association of Pro12Ala polymorphism in PPARγ2 with lower carotid artery IMT in Japanese,” Diabetes Research and Clinical Practice, vol. 62, no. 1, pp. 55–59, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Temelkova-Kurktschiev, M. Hanefeld, G. Chinetti et al., “Ala12Ala genotype of the peroxisome proliferator-activated receptor γ2 protects against atherosclerosis,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 9, pp. 4238–4242, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Z. Al-Shali, A. A. House, A. J. G. Hanley et al., “Genetic variation in PPARG encoding peroxisome proliferator-activated receptor γ associated with carotid atherosclerosis,” Stroke, vol. 35, no. 9, pp. 2036–2040, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. R. McPherson, A. Pertsemlidis, N. Kavaslar et al., “A common allele on chromosome 9 associated with coronary heart disease,” Science, vol. 316, no. 5830, pp. 1488–1491, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Helgadottir, G. Thorleifsson, A. Manolescu et al., “A common variant on chromosome 9p21 affects the risk of myocardial infarction,” Science, vol. 316, no. 5830, pp. 1491–1493, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. N. J. Samani, J. Erdmann, A. S. Hall et al., “Genomewide association analysis of coronary artery disease,” The New England Journal of Medicine, vol. 357, no. 5, pp. 443–453, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. P. R. Burton, D. G. Clayton, L. R. Cardon et al., “Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls,” Nature, vol. 447, no. 7145, pp. 661–678, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Erdmann, A. Grosshennig, P. S. Braund et al., “New susceptibility locus for coronary artery disease on chromosome 3q22.3,” Nature Genetics, vol. 41, no. 3, pp. 280–282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. D. A. Tregouet, I. R. Konig, J. Erdmann et al., “Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease,” Nature Genetics, vol. 41, no. 3, pp. 283–285, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Horiki, H. Ikegami, T. Fujisawa et al., “Association of Pro12Ala polymorphism of PPARgamma gene with insulin resistance and related diseases,” Diabetes Research and Clinical Practice, vol. 66, supplement 1, pp. S63–S67, 2004. View at Google Scholar
  44. F. J. Rodríguez-Esparragón, J. C. Rodríguez-Pérez, A. Macías-Reyes, and F. Alamo-Santana, “Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are associated with essential hypertension,” Journal of Hypertension, vol. 21, no. 9, pp. 1649–1655, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. C. J. Östgren, U. Lindblad, O. Melander, A. Melander, L. Groop, and L. Råstam, “Peroxisome proliferator-activated receptor-γ Pro12Ala polymorphism and the association with blood pressure in type 2 diabetes: skaraborg hypertension and diabetes project,” Journal of Hypertension, vol. 21, no. 9, pp. 1657–1662, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. S. J. Hasstedt, Q.-F. Ren, K. Teng, and S. C. Elbein, “Effect of the peroxisome proliferator-activated receptor-γ2 Pro12Ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 2, pp. 536–541, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. J. A. Douglas, M. R. Erdos, R. M. Watanabe et al., “The peroxisome poliferator—activated receptor-γ2 Pro 12Ala variant: association with type 2 diabetes and trait differences,” Diabetes, vol. 50, no. 4, pp. 886–890, 2001. View at Google Scholar · View at Scopus
  48. Y. Mori, H. Kim-Motoyama, T. Katakura et al., “Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor γ2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men,” Biochemical and Biophysical Research Communications, vol. 251, no. 1, pp. 195–198, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. I. Gouni-Berthold, E. Giannakidou, D. Müller-Wieland et al., “Peroxisome proliferator-activated receptor-γ2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2,” Journal of Hypertension, vol. 23, no. 2, pp. 301–308, 2005. View at Publisher · View at Google Scholar · View at Scopus